{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T05:45:23Z","timestamp":1791265523159,"version":"4.1.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,7,11]],"date-time":"2023-07-11T00:00:00Z","timestamp":1689033600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,11]],"date-time":"2023-07-11T00:00:00Z","timestamp":1689033600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004040","name":"KU Leuven","doi-asserted-by":"publisher","award":["C3\/19\/057"],"award-info":[{"award-number":["C3\/19\/057"]}],"id":[{"id":"10.13039\/501100004040","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010661","name":"EC | Horizon 2020 Framework Programme","doi-asserted-by":"publisher","award":["733176"],"award-info":[{"award-number":["733176"]}],"id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Flemish Research Foundation (FWO) Excellence of Science (EOS) program"},{"name":"V.L. acknowledges a research assistant fellowship from KU Leuven"},{"name":"J.M. grant support from the Chinese Scholarship Council"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Ebola virus (EBOV) and related filoviruses such as Sudan virus (SUDV) threaten global public health. Effective filovirus vaccines are available only for EBOV, yet restricted to emergency use considering a high reactogenicity and demanding logistics. Here we present YF-EBO, a live YF17D-vectored dual-target vaccine candidate expressing EBOV glycoprotein (GP) as protective antigen. Safety of YF-EBO in mice was further improved over that of parental YF17D vaccine. A single dose of YF-EBO was sufficient to induce high levels of EBOV GP-specific antibodies and cellular immune responses, that protected against lethal infection using EBOV GP-pseudotyped recombinant vesicular stomatitis virus (rVSV-EBOV) in interferon-deficient (<jats:italic>Ifnar<\/jats:italic><jats:sup>-\/-<\/jats:sup>) mice as surrogate challenge model. Concomitantly induced yellow fever virus (YFV)-specific immunity protected <jats:italic>Ifnar<\/jats:italic><jats:sup>-\/-<\/jats:sup> mice against intracranial YFV challenge. YF-EBO could thus help to simultaneously combat both EBOV and YFV epidemics. Finally, we demonstrate how to target other highly pathogenic filoviruses such as SUDV at the root of the 2022 outbreak in Uganda.<\/jats:p>","DOI":"10.1038\/s41541-023-00699-7","type":"journal-article","created":{"date-parts":[[2023,7,11]],"date-time":"2023-07-11T07:02:22Z","timestamp":1689058942000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["YF17D-vectored Ebola vaccine candidate protects mice against lethal surrogate Ebola and yellow fever virus challenge"],"prefix":"10.1038","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2507-9029","authenticated-orcid":false,"given":"Viktor","family":"Lemmens","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"Kelchtermans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Debaveye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winston","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Vercruysse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0912-2632","authenticated-orcid":false,"given":"Ji","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hendrik Jan","family":"Thibaut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Neyts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6928-0931","authenticated-orcid":false,"given":"Lorena","family":"Sanchez-Felipe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8117-9166","authenticated-orcid":false,"given":"Kai","family":"Dallmeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,11]]},"reference":[{"key":"699_CR1","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1016\/S0140-6736(18)33132-5","volume":"393","author":"D Malvy","year":"2019","unstructured":"Malvy, D., McElroy, A. K., de Clerck, H., G\u00fcnther, S. & van Griensven, J. Ebola virus disease. Lancet 393, 936\u2013948 (2019).","journal-title":"Lancet"},{"key":"699_CR2","doi-asserted-by":"publisher","first-page":"S698","DOI":"10.1093\/infdis\/jiy213","volume":"218","author":"C Huber","year":"2018","unstructured":"Huber, C., Finelli, L. & Stevens, W. The economic and social burden of the 2014 Ebola outbreak in West Africa. J. Infect. Dis. 218, S698\u2013S704 (2018).","journal-title":"J. Infect. Dis."},{"key":"699_CR3","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/S0140-6736(16)32621-6","volume":"389","author":"AM Henao-Restrepo","year":"2017","unstructured":"Henao-Restrepo, A. M. et al. Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola \u00c7a Suffit!). Lancet 389, 505\u2013518 (2017).","journal-title":"Lancet"},{"key":"699_CR4","unstructured":"WHO. Preliminary results on the efficacy of rVSV-ZEBOV-GP Ebola vaccine using the ring vaccination strategy in the control of an Ebola outbreak in the Democratic Republic of the Congo: an example of integration of research into epidemic response. https:\/\/www.who.int\/publications\/m\/item\/preliminary-results-on-the-efficacy-of-rvsv-zebov-gp-ebola-vaccine-using-the-strategy-in-the-control-of-an-ebola-outbreak (2019)."},{"key":"699_CR5","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1056\/NEJMoa1502924","volume":"374","author":"ST Agnandji","year":"2016","unstructured":"Agnandji, S. T. et al. Phase 1 trials of rVSV Ebola vaccine in Africa and Europe. N. Engl. J. Med. 374, 1647\u20131660 (2016).","journal-title":"N. Engl. J. Med."},{"key":"699_CR6","doi-asserted-by":"publisher","first-page":"taab086","DOI":"10.1093\/jtm\/taab086","volume":"28","author":"L Carnino","year":"2021","unstructured":"Carnino, L. et al. Feasibility and safety of rVSV-ZEBOV vaccination of humanitarian health workers against Ebola virus disease: an observational study. J. Travel Med. 28, taab086 (2021).","journal-title":"J. Travel Med."},{"key":"699_CR7","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1016\/S1473-3099(15)00154-1","volume":"15","author":"A Huttner","year":"2015","unstructured":"Huttner, A. et al. The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1\/2 trial. Lancet Infect. Dis. 15, 1156\u20131166 (2015).","journal-title":"Lancet Infect. Dis."},{"key":"699_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41541-020-00261-9","volume":"5","author":"R Roozendaal","year":"2020","unstructured":"Roozendaal, R. et al. Nonhuman primate to human immunobridging to infer the protective effect of an Ebola virus vaccine candidate. Npj Vaccines 5, 1\u201311 (2020).","journal-title":"Npj Vaccines"},{"key":"699_CR9","doi-asserted-by":"publisher","first-page":"e1010078","DOI":"10.1371\/journal.ppat.1010078","volume":"17","author":"C Woolsey","year":"2021","unstructured":"Woolsey, C. & Geisbert, T. W. Current state of Ebola virus vaccines: a snapshot. PLoS Pathog. 17, e1010078 (2021).","journal-title":"PLoS Pathog."},{"key":"699_CR10","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1038\/s41591-021-01313-w","volume":"27","author":"DG Bausch","year":"2021","unstructured":"Bausch, D. G. The need for a new strategy for Ebola vaccination. Nat. Med. 27, 580\u2013581 (2021).","journal-title":"Nat. Med."},{"key":"699_CR11","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/S1473-3099(21)00226-7","volume":"22","author":"ST Agnandji","year":"2022","unstructured":"Agnandji, S. T. & Loembe, M. M. Ebola vaccines for mass immunisation in affected regions. Lancet Infect. Dis. 22, 8\u201310 (2022).","journal-title":"Lancet Infect. Dis."},{"key":"699_CR12","doi-asserted-by":"publisher","first-page":"e1001638","DOI":"10.1371\/journal.pmed.1001638","volume":"11","author":"T Garske","year":"2014","unstructured":"Garske, T. et al. Yellow fever in Africa: estimating the burden of disease and impact of mass vaccination from outbreak and serological data. PLoS Med 11, e1001638 (2014).","journal-title":"PLoS Med"},{"key":"699_CR13","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1126\/science.aau8225","volume":"361","author":"ADT Barrett","year":"2018","unstructured":"Barrett, A. D. T. The reemergence of yellow fever. Science 361, 847\u2013848 (2018).","journal-title":"Science"},{"key":"699_CR14","doi-asserted-by":"publisher","first-page":"891","DOI":"10.3390\/ph14090891","volume":"14","author":"CA Hansen","year":"2021","unstructured":"Hansen, C. A. & Barrett, A. D. T. The present and future of yellow fever vaccines. Pharmaceuticals 14, 891 (2021).","journal-title":"Pharmaceuticals"},{"key":"699_CR15","doi-asserted-by":"publisher","first-page":"1895644","DOI":"10.1080\/21645515.2021.1895644","volume":"18","author":"G Montalvo Zurbia-Flores","year":"2022","unstructured":"Montalvo Zurbia-Flores, G., Rollier, C. S. & Reyes-Sandoval, A. Re-thinking yellow fever vaccines: fighting old foes with new generation vaccines. Hum. Vaccines Immunother. 18, 1895644 (2022).","journal-title":"Hum. Vaccines Immunother."},{"key":"699_CR16","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1038\/nri2629","volume":"9","author":"B Pulendran","year":"2009","unstructured":"Pulendran, B. Learning immunology from the yellow fever vaccine: innate immunity to systems vaccinology. Nat. Rev. Immunol. 9, 741\u2013747 (2009).","journal-title":"Nat. Rev. Immunol."},{"key":"699_CR17","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.4161\/hv.28117","volume":"10","author":"MC Bonaldo","year":"2014","unstructured":"Bonaldo, M. C., Sequeira, P. C. & Galler, R. The yellow fever 17D virus as a platform for new live attenuated vaccines. Hum. Vaccines Immunother. 10, 1256\u20131265 (2014).","journal-title":"Hum. Vaccines Immunother."},{"key":"699_CR18","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1038\/s41586-020-3035-9","volume":"590","author":"L Sanchez-Felipe","year":"2021","unstructured":"Sanchez-Felipe, L. et al. A single-dose live-attenuated YF17D-vectored SARS-CoV-2 vaccine candidate. Nature 590, 320\u2013325 (2021).","journal-title":"Nature"},{"key":"699_CR19","doi-asserted-by":"crossref","unstructured":"Meier, K. C., Gardner, C. L., Khoretonenko, M. V., Klimstra, W. B. & Ryman, K. D. A mouse model for studying viscerotropic disease caused by yellow fever virus infection. PLoS Pathog. 5, e1000614 (2009).","DOI":"10.1371\/journal.ppat.1000614"},{"key":"699_CR20","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.1080\/22221751.2021.2008772","volume":"10","author":"J Ma","year":"2021","unstructured":"Ma, J. et al. Comparing immunogenicity and protective efficacy of the yellow fever 17D vaccine in mice. Emerg. Microbes Infect. 10, 2279\u20132290 (2021).","journal-title":"Emerg. Microbes Infect."},{"key":"699_CR21","doi-asserted-by":"crossref","unstructured":"Duehr, J. et al. Novel cross-reactive monoclonal antibodies against ebolavirus glycoproteins show protection in a murine challenge model. J. Virol. 91, e00652-17 (2017).","DOI":"10.1128\/JVI.00652-17"},{"key":"699_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-29401-x","volume":"8","author":"J Emanuel","year":"2018","unstructured":"Emanuel, J. et al. A VSV-based Zika virus vaccine protects mice from lethal challenge. Sci. Rep. 8, 11043 (2018).","journal-title":"Sci. Rep."},{"key":"699_CR23","doi-asserted-by":"publisher","first-page":"e1005786","DOI":"10.1371\/journal.ppat.1005786","volume":"12","author":"AM Watson","year":"2016","unstructured":"Watson, A. M., Lam, L. K. M., Klimstra, W. B. & Ryman, K. D. The 17D-204 vaccine strain-induced protection against virulent yellow fever virus is mediated by humoral immunity and CD4+ but not CD8+ T cells. PLoS Pathog. 12, e1005786 (2016).","journal-title":"PLoS Pathog."},{"key":"699_CR24","doi-asserted-by":"publisher","first-page":"100499","DOI":"10.1016\/j.xcrm.2021.100499","volume":"3","author":"B Neumann","year":"2022","unstructured":"Neumann, B. et al. Antibodies against viral nucleo-, phospho-, and X protein contribute to serological diagnosis of fatal Borna disease virus 1 infections. Cell Rep. Med. 3, 100499 (2022).","journal-title":"Cell Rep. Med."},{"key":"699_CR25","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1056\/NEJMoa1410863","volume":"376","author":"JE Ledgerwood","year":"2017","unstructured":"Ledgerwood, J. E. et al. Chimpanzee adenovirus vector Ebola vaccine. N. Engl. J. Med. 376, 928\u2013938 (2017).","journal-title":"N. Engl. J. Med."},{"key":"699_CR26","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.ebiom.2019.09.055","volume":"49","author":"A Marzi","year":"2019","unstructured":"Marzi, A. et al. Single low-dose VSV-EBOV vaccination protects cynomolgus macaques from lethal Ebola challenge. EBioMedicine 49, 223\u2013231 (2019).","journal-title":"EBioMedicine"},{"key":"699_CR27","doi-asserted-by":"publisher","first-page":"e00479","DOI":"10.1128\/JVI.00479-17","volume":"91","author":"NJ Lennemann","year":"2017","unstructured":"Lennemann, N. J. et al. Vesicular stomatitis virus pseudotyped with Ebola virus glycoprotein serves as a protective, noninfectious vaccine against Ebola virus challenge in mice. J. Virol. 91, e00479\u201317 (2017).","journal-title":"J. Virol."},{"key":"699_CR28","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1006\/viro.2002.1432","volume":"296","author":"RG van der Most","year":"2002","unstructured":"van der Most, R. G., Harrington, L. E., Giuggio, V., Mahar, P. L. & Ahmed, R. Yellow fever virus 17D envelope and NS3 proteins are major targets of the antiviral T cell response in mice. Virology 296, 117\u2013124 (2002).","journal-title":"Virology"},{"key":"699_CR29","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1586\/14760584.2013.836320","volume":"12","author":"P Cottin","year":"2013","unstructured":"Cottin, P., Niedrig, M. & Domingo, C. Safety profile of the yellow fever vaccine Stamaril\u00ae: a 17-year review. Expert Rev. Vaccines 12, 1351\u20131368 (2013).","journal-title":"Expert Rev. Vaccines"},{"key":"699_CR30","first-page":"269","volume":"88","author":"WHO.","year":"2013","unstructured":"WHO. Vaccines and vaccination against yellow fever. WHO position paper \u2013 June 2013. Wkly. Epidemiol. Rec. 88, 269\u2013283 (2013).","journal-title":"Wkly. Epidemiol. Rec."},{"key":"699_CR31","doi-asserted-by":"publisher","first-page":"5769","DOI":"10.1016\/j.vaccine.2014.08.051","volume":"32","author":"SJ Seligman","year":"2014","unstructured":"Seligman, S. J. Risk groups for yellow fever vaccine-associated viscerotropic disease (YEL-AVD). Vaccine 32, 5769\u20135775 (2014).","journal-title":"Vaccine"},{"key":"699_CR32","doi-asserted-by":"publisher","first-page":"taaa172","DOI":"10.1093\/jtm\/taaa172","volume":"27","author":"E Lecomte","year":"2020","unstructured":"Lecomte, E. et al. A clinician\u2019s perspective on yellow fever vaccine-associated neurotropic disease. J. Travel Med. 27, taaa172 (2020).","journal-title":"J. Travel Med."},{"key":"699_CR33","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.omtm.2022.03.010","volume":"25","author":"L-H Li","year":"2022","unstructured":"Li, L.-H. et al. Biodistribution and environmental safety of a live-attenuated YF17D-vectored SARS-CoV-2 vaccine candidate. Mol. Ther. Methods Clin. Dev. 25, 215\u2013224 (2022).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"699_CR34","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.virol.2014.01.017","volume":"452\u2013453","author":"MG de Santana","year":"2014","unstructured":"de Santana, M. G. et al. Improved genetic stability of recombinant yellow fever 17D virus expressing a lentiviral Gag gene fragment. Virology 452\u2013453, 202\u2013211 (2014).","journal-title":"Virology"},{"key":"699_CR35","doi-asserted-by":"publisher","first-page":"75","DOI":"10.4269\/ajtmh.1995.52.75","volume":"52","author":"RS Marchevsky","year":"1995","unstructured":"Marchevsky, R. S. et al. Phenotypic analysis of yellow fever virus derived from complementary DNA. Am. J. Trop. Med. Hyg. 52, 75\u201380 (1995).","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"699_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-018-0092-2","volume":"3","author":"DB Kum","year":"2018","unstructured":"Kum, D. B. et al. A yellow fever\u2013Zika chimeric virus vaccine candidate protects against Zika infection and congenital malformations in mice. Npj Vaccines 3, 56 (2018).","journal-title":"Npj Vaccines"},{"key":"699_CR37","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1016\/j.celrep.2019.01.069","volume":"26","author":"IL McWilliams","year":"2019","unstructured":"McWilliams, I. L. et al. Pseudovirus rVSV\u0394G-ZEBOV-GP infects neurons in retina and CNS, causing apoptosis and neurodegeneration in neonatal mice. Cell Rep. 26, 1718\u20131726.e4 (2019).","journal-title":"Cell Rep."},{"key":"699_CR38","doi-asserted-by":"publisher","first-page":"S404","DOI":"10.1093\/infdis\/jiv188","volume":"212","author":"A Marzi","year":"2015","unstructured":"Marzi, A. et al. Stat1-deficient mice are not an appropriate model for efficacy testing of recombinant vesicular stomatitis virus\u2013based filovirus vaccines. J. Infect. Dis. 212, S404\u2013S409 (2015).","journal-title":"J. Infect. Dis."},{"key":"699_CR39","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.tim.2018.08.008","volume":"27","author":"M Meyer","year":"2019","unstructured":"Meyer, M., Malherbe, D. C. & Bukreyev, A. Can Ebola virus vaccines have universal immune correlates of protection? Trends Microbiol 27, 8\u201316 (2019).","journal-title":"Trends Microbiol"},{"key":"699_CR40","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1073\/pnas.1209591110","volume":"110","author":"A Marzi","year":"2013","unstructured":"Marzi, A. et al. Antibodies are necessary for rVSV\/ZEBOV-GP\u2013mediated protection against lethal Ebola virus challenge in nonhuman primates. Proc. Natl Acad. Sci. USA 110, 1893\u20131898 (2013).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"699_CR41","doi-asserted-by":"publisher","first-page":"12392","DOI":"10.1128\/JVI.02149-13","volume":"87","author":"AK Erickson","year":"2013","unstructured":"Erickson, A. K. & Pfeiffer, J. K. Dynamic viral dissemination in mice infected with yellow fever virus strain 17D. J. Virol. 87, 12392\u201312397 (2013).","journal-title":"J. Virol."},{"key":"699_CR42","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1126\/science.8009221","volume":"264","author":"U M\u00fcller","year":"1994","unstructured":"M\u00fcller, U. et al. Functional role of type I and type II interferons in antiviral defense. Science 264, 1918\u20131921 (1994).","journal-title":"Science"},{"key":"699_CR43","unstructured":"WHO. Eliminate yellow fever epidemics (EYE) strategy 2017-2026. https:\/\/www.who.int\/initiatives\/eye-strategy (2023)."},{"key":"699_CR44","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1093\/cid\/ciw601","volume":"63","author":"B Diallo","year":"2016","unstructured":"Diallo, B. et al. Resurgence of Ebola virus disease in Guinea linked to a survivor with virus persistence in seminal fluid for more than 500 days. Clin. Infect. Dis. 63, 1353\u20131356 (2016).","journal-title":"Clin. Infect. Dis."},{"key":"699_CR45","doi-asserted-by":"publisher","first-page":"e82","DOI":"10.1016\/S1473-3099(16)00077-3","volume":"16","author":"P Vetter","year":"2016","unstructured":"Vetter, P., Kaiser, L., Schibler, M., Ciglenecki, I. & Bausch, D. G. Sequelae of Ebola virus disease: the emergency within the emergency. Lancet Infect. Dis. 16, e82\u2013e91 (2016).","journal-title":"Lancet Infect. Dis."},{"key":"699_CR46","doi-asserted-by":"publisher","first-page":"2448","DOI":"10.1056\/NEJMoa1509773","volume":"373","author":"SE Mate","year":"2015","unstructured":"Mate, S. E. et al. Molecular evidence of sexual transmission of Ebola virus. N. Engl. J. Med. 373, 2448\u20132454 (2015).","journal-title":"N. Engl. J. Med."},{"key":"699_CR47","doi-asserted-by":"publisher","first-page":"ofz482","DOI":"10.1093\/ofid\/ofz482","volume":"6","author":"AK Keita","year":"2019","unstructured":"Keita, A. K. et al. A 40-month follow-up of Ebola virus disease survivors in Guinea (PostEbogui) reveals long-term detection of Ebola viral ribonucleic acid in semen and breast milk. Open Forum Infect. Dis. 6, ofz482 (2019).","journal-title":"Open Forum Infect. Dis."},{"key":"699_CR48","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/s41586-021-03901-9","volume":"597","author":"AK Keita","year":"2021","unstructured":"Keita, A. K. et al. Resurgence of Ebola virus in 2021 in Guinea suggests a new paradigm for outbreaks. Nature 597, 539\u2013543 (2021).","journal-title":"Nature"},{"key":"699_CR49","doi-asserted-by":"crossref","unstructured":"Ma, J. et al. Live-attenuated YF17D-vectored COVID-19 vaccine protects from lethal yellow fever virus infection in mouse and hamster models. eBioMedicine 83, 104240 (2022).","DOI":"10.1016\/j.ebiom.2022.104240"},{"key":"699_CR50","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.jviromet.2010.08.006","volume":"169","author":"MA Whitt","year":"2010","unstructured":"Whitt, M. A. Generation of VSV pseudotypes using recombinant \u0394G-VSV for studies on virus entry, identification of entry inhibitors, and immune responses to vaccines. J. Virol. Methods 169, 365\u2013374 (2010).","journal-title":"J. Virol. Methods"},{"key":"699_CR51","doi-asserted-by":"publisher","first-page":"4477","DOI":"10.1073\/pnas.92.10.4477","volume":"92","author":"ND Lawson","year":"1995","unstructured":"Lawson, N. D., Stillman, E. A., Whitt, M. A. & Rose, J. K. Recombinant vesicular stomatitis viruses from DNA. Proc. Natl Acad. Sci. USA 92, 4477\u20134481 (1995).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"699_CR52","doi-asserted-by":"publisher","first-page":"2196","DOI":"10.1080\/21645515.2020.1765621","volume":"16","author":"S Sharma","year":"2020","unstructured":"Sharma, S. et al. Small-molecule inhibitors of TBK1 serve as an adjuvant for a plasmid-launched live-attenuated yellow fever vaccine. Hum. Vaccines Immunother. 16, 2196\u20132203 (2020).","journal-title":"Hum. Vaccines Immunother."},{"key":"699_CR53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ab.2012.10.031","volume":"434","author":"K Dallmeier","year":"2013","unstructured":"Dallmeier, K. & Neyts, J. Simple and inexpensive three-step rapid amplification of cDNA 5\u2019 ends using 5\u2019 phosphorylated primers. Anal. Biochem. 434, 1\u20133 (2013).","journal-title":"Anal. Biochem."},{"key":"699_CR54","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.virol.2005.12.001","volume":"345","author":"PJ Bredenbeek","year":"2006","unstructured":"Bredenbeek, P. J. et al. A recombinant yellow fever 17D vaccine expressing Lassa virus glycoproteins. Virology 345, 299\u2013304 (2006).","journal-title":"Virology"},{"key":"699_CR55","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1080\/22221751.2019.1694394","volume":"8","author":"DB Kum","year":"2019","unstructured":"Kum, D. B. et al. Limited evolution of the yellow fever virus 17d in a mouse infection model. Emerg. Microbes Infect. 8, 1734\u20131746 (2019).","journal-title":"Emerg. Microbes Infect."},{"key":"699_CR56","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-34439-7","volume":"13","author":"S Sharma","year":"2022","unstructured":"Sharma, S. et al. Updated vaccine protects against SARS-CoV-2 variants including Omicron (B.1.1.529) and prevents transmission in hamsters. Nat. Commun. 13, 6644 (2022).","journal-title":"Nat. Commun."},{"key":"699_CR57","doi-asserted-by":"publisher","first-page":"e02548","DOI":"10.1128\/spectrum.02548-21","volume":"10","author":"M Rasulova","year":"2022","unstructured":"Rasulova, M. et al. A high-throughput yellow fever neutralization assay. Microbiol. Spectr. 10, e02548\u201321 (2022).","journal-title":"Microbiol. Spectr."},{"key":"699_CR58","doi-asserted-by":"crossref","unstructured":"Ferrara, F. & Temperton, N. Pseudotype neutralization assays: from laboratory bench to data analysis. Methods Protoc. 1, 8 (2018).","DOI":"10.3390\/mps1010008"},{"key":"699_CR59","doi-asserted-by":"publisher","first-page":"3022","DOI":"10.1093\/molbev\/msab120","volume":"38","author":"K Tamura","year":"2021","unstructured":"Tamura, K., Stecher, G. & Kumar, S. MEGA11: molecular evolutionary genetics analysis version 11. Mol. Biol. Evol. 38, 3022\u20133027 (2021).","journal-title":"Mol. Biol. Evol."}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-023-00699-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-023-00699-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-023-00699-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,11]],"date-time":"2023-07-11T08:04:43Z","timestamp":1689062683000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-023-00699-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,11]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["699"],"URL":"https:\/\/doi.org\/10.1038\/s41541-023-00699-7","relation":{},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,11]]},"assertion":[{"value":"13 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"K.D., L.S.-F., V.L., and J.N. are mentioned as inventors on patent applications related to the discovery and use of YF17D-vectored filovirus vaccines. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"99"}}